Andrii Buvailo, Ph.D.: LinkedIn Content Strategy & Writing Style

This AI unicorn, backed by NVIDIA and Google, just unveiled AQAffinity, a new open-source model aimed at accelerating early-stage drug discovery 🔥. Launched by SandboxAQ, AQAffinity is a protein–lig…

BREAKING: Eli Lilly and Company bets $2.4 billion to acquire next-gen in vivo cell therapy platform Orna Therapeutics💰 The US pharma giant has entered into a definitive agreement to acquire Orna Th…

What is AI-driven drug discovery, really? Is it even a big deal in 2026? Back in 2025, I co-authored an industry report that proposed a clear, qualitative framework for what should actually count as…

BREAKING: AstraZeneca just put $1.2B upfront, and up to $17B potentially, behind a China-sourced obesity pipeline 💰. The UK pharma giant just made one of the largest China-to-West biopharma bets yet…

The 10 largest pharma companies by market cap in 2026, and some growth drivers... This year, I am shifting my focus a bit towards big pharma strategy, and so here is a useful brief snapshot of the l…

Here are 3 real-life AI uses beyond the drug discovery hype, according to Diogo Rau, CIDO at Eli Lilly. With Lilly announcing a $1B AI innovation lab with Nvidia, most headlines focused on AI-powered…